Scalper1 News
Big pharma AbbVie (ABBV) beat analysts’ Q3 estimates and issued five-year guidance that was above expectations Friday morning, sending the stock up sharply in early trading. AbbVie’s adjusted earnings rose 27% over the year-earlier quarter to $1.13 a share, beating analysts’ consensus by 5 cents, according to Thomson Reuters. Sales climbed 18% to $5.95 billion, about $50 million above estimates. AbbVie tightened its full-year EPS guidance range to Scalper1 News
Scalper1 News